KFDA approves Nycomed’s oral COPD therapy

Nycomed Korea has announced that Daxas (roflumilast) was approved by the Korea Food and Drug Administration as an oral treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

COPD is an under-diagnosed, progressive, irreversible lung disease. Symptoms of COPD in...